Aprea Therapeutics updates patent portfolio to 28 issued patents

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Aprea Therapeutics updates patent portfolio to 28 issued patents

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

August 28, 2026 8:15 AM EDT

Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents

DOYLESTOWN, Pa., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (Aprea, or the Company), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today provided an update on its existing patent portfolio.

Our expanding patent portfolio reflects Apreas commitment to innovation and building a differentiated leadership position in precision medicine, said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. A strong global intellectual property portfolio is a... More